 Home > Biochemistry News > Biotechnology News > mRNA COVID-19 vaccine shows good stability and immunogenicity in preclinical studies

mRNA COVID-19 vaccine shows good stability and immunogenicity in preclinical studies

 Last Update: 2022-05-01
 Source: Internet
 Author: User

Tags

acetaminophen high dose

pool chemical levels

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On February 12, Ruike Biotech announced the preclinical data of its subsidiary Wuhan Ruikeji Biotechnology Co.

According to the paper, Rikage Biotech has developed lyophilized mRNA-LNP vaccines against COVID-19 of the prototype strain, Delta strain and Omicron strain respectively.

The freeze-drying process does not affect the key physical and chemical indicators of the vaccine, achieving formulation stability at 4°C and 25°C

The lyophilization process does not affect the biological activity and immunogenicity of mRNA vaccines

Sequence-optimized lyophilized mRNA vaccine induces robust immune responses and high neutralizing antibody titers

Two doses of mRNA vaccine immunization 14 days apart provided complete protection against Delta strain challenge in hACE2 transgenic mice challenge assay

The new crown epidemic has ravaged the world for more than two years, and new mutant strains are constantly emerging

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Lyophilized mRNA COVID-19 Vaccine Shows Good Stability and Immunogenicity in Preclinical Studies Press Release

03-08

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

mRNA COVID-19 vaccine shows good stability and immunogenicity in preclinical studies

Related Articles

Lyophilized mRNA COVID-19 Vaccine Shows Good Stability and Immunogenicity in Preclinical Studies Press Release